
Fwd: Opioids: Additional Manufacturer Settlements (attorney client settlement communication)

From Mike Espy <mikesmike@mikespy.com>

Date Tue 7/15/2025 1:28 PM

To Greg Higginbotham <greg.higginbotham@madison-co.com>; Shayna E. Sacks <SSacks@Napolilaw.com>

CAUTION! External Content. Please use caution when opening attachments and links. Do not provide your username and password if requested.

Greg- I recommend that the county participate.

Begin forwarded message:

From: "Shayna E. Sacks" <SSacks@Napolilaw.com>

Subject: Opioids: Additional Manufacturer Settlements (attorney client settlement communication)

Date: July 15, 2025 at 1:12:38 PM CDT

To: "mike@mikespy.com" <mike@mikespy.com>, "greg.higginbotham@madison-co.com" <greg.higginbotham@madison-co.com>

Cc: "mike@mikespy.com" <mike@mikespy.com>

We are happy to notify you of a new opioid settlement opportunity that will resolve all of your claims against each of the below small manufacturer companies in one participation agreement. These settlements will collectively add an additional \$1.1 billion in cash and pharmaceutical product to be distributed among state and local governments across the country.

1. Alvogen, Inc.;
2. Amneal Pharmaceuticals, Inc.;
3. Apotex Inc.;
4. Hikma Pharmaceuticals USA Inc.;
5. Indivior Inc.;
6. Mylan Pharmaceuticals Inc.;
7. Sun Pharmaceutical Industries, Inc.; and
8. Zydus Pharmaceuticals (USA), Inc.

We recommend that you join this settlement group by signing and returning the Participation Agreement via DocuSign.

Six of the nine settlements will be paid out in the first year, with the remaining three (Amneal, Indivior and Mylan) paid over a period of between two and ten years. Three of the settlements include opioids overdose product such as Naloxone. Eight

of the settlement also contain injunctive relief concerning their opioid marketing and suspicious monitoring programs that will be overseen by the States.

You do not need to have sued these companies in order to participate in these settlements. This settlement group will utilize the same allocation formula as the prior national agreements. This means that your state will receive the same share of the settlements that they have in the past pursuant to the state agreement, and the local governments will receive funding under the same process as in previous national settlements. As in past deals, attorney fees and costs will be paid out of a separate fund.

This notice is different than the notice you recently received from Rubris concerning a settlement with Purdue Pharma, L.P., and the Sackler Family. You may participate in the settlements discussed in this notice regardless of whether you join the Purdue and Sackler settlement.

You will receive a *Notice* this week, and a *Participation Agreement* with other documents to consider, directly from Rubris in July/August 2025. There will be one *Participation Agreement* for the entire settlement group. **You will need to obtain the necessary authorization and submit the Settlement Participation Agreement for this settlement group on or before September 30, 2025.**

I am available as always to discuss. Hope you are well.

Shayna E. Sacks
Partner

Shayna E. Sacks

Partner

Admitted in: NY, NJ, CT

 Official Napoli Shkolnik Logo

(212) 397-1000 | SSacks@NapoliLaw.com

360 Lexington Avenue, Eleventh Floor, New York, NY 10017 | [vCard](#)

Our Mission Statement

Notice: This communication, including attachments, may contain information that is confidential and protected by the attorney/client or other privileges. It constitutes non-public information intended to be conveyed only to the designated recipient(s). If the reader or recipient of this communication is not the intended recipient, an employee or agent of the intended recipient who is responsible for delivering it to the intended recipient, or you believe that you have received this communication in error, please notify the sender immediately by return e-mail and promptly delete this e-mail, including attachments without reading or saving them in any manner. The unauthorized use, dissemination, distribution, or reproduction of this e-mail including attachments, is prohibited and may be unlawful. Receipt by anyone other than the intended recipient(s) is not a waiver of any attorney/client or other privilege.

This e-mail and all other electronic (including voice) communications from the sender's firm are for informational purposes only. No such

communication is intended by the sender to constitute either an electronic record or an electronic signature, or to constitute any agreement by the sender to conduct a transaction by electronic means. Any such intention or agreement is hereby expressly disclaimed unless otherwise specifically indicated.